WHO Sounds Alert Over Acute Lack of Obesity Medications
Fewer than 10% of patients who could benefit from weight-loss injections such as Wegovy are able to get them, warns the World Health Organization as it releases its first advice on the medications.
Given over a billion people worldwide currently obese, it is urging increased and just availability to this class of drugs.
Per estimates, over two billion could be obese by 2030 without intervention.
"The latest guidelines recognises that obesity is a long-term condition that can be treated with thorough and lifelong treatment," said the agency's head Tedros Adhanom Ghebreyesus.
Substantial prices, insufficient output, and logistical bottlenecks are key obstacles to broad availability to the injections that can aid individuals in losing significant body mass, notes the organization.
Skinny Jab Supply Crisis
Even in the current best projected case, the supply of these medications might only reach approximately 100 million people – fewer than 10% of the global need, as stated by the health organization.
The guideline encourages nations and manufacturers to expand availability, by approaches like voluntary licensing.
The intellectual property rights on the active ingredient – the core component of the drug Wegovy – is scheduled to end in a number of nations in 2026.
How Obesity Injections Operate
The injections mimick a body's own hormone to slow digestion, suppress the appetite and enhance the sense of being full so users reduce food intake.
People commonly see weight reduction in the initial weeks of commencing the regular doses.
Evidence indicates users may regain a significant portion a year later of stopping the medication, because their usual hunger return.
Being above a healthy weight increases your risk for developing medical conditions, like diabetes, cardiovascular issues, stroke, and specific malignancies.
Obesity impacts individuals in every country and was responsible for millions of fatalities worldwide in 2024, as per the WHO.
